PCSK9 Inhibitors Class Overview Monograph

What Are PCSK9 Inhibitors and How Do They Work?

PCSK9 inhibitors block the PCSK9 enzyme, which normally tags hepatic LDL receptors for lysosomal destruction. By neutralizing PCSK9, these agents allow LDL receptors to recycle to the hepatocyte surface, dramatically increasing LDL particle clearance from plasma. The net result is a 50 to 65% reduction in LDL-C independent of statin background therapy.

The PCSK9 Enzyme: A Brief Primer

PCSK9 is a serine protease secreted primarily by hepatocytes. After LDL binds its receptor and the complex is internalized, PCSK9 binds the LDL receptor in the endosome and redirects it toward lysosomal degradation rather than receptor recycling. Loss-of-function mutations in PCSK9, identified in the Dallas Heart Study cohort, were associated with 88% lower lifetime ASCVD risk in carriers versus non-carriers, establishing the causal biology that drug developers then targeted. [1]

Mechanisms Across Agent Subtypes

The three approved subtypes target PCSK9 through distinct mechanisms:

• Monoclonal antibodies (evolocumab, alirocumab): Bind circulating PCSK9 protein directly, preventing it from binding the LDL receptor. Peak effect within 4 hours of subcutaneous injection; half-life approximately 11 to 20 days.
• Small interfering RNA (inclisiran): Delivered as inclisiran sodium, it enters hepatocytes via GalNAc conjugation and silences PCSK9 mRNA, reducing hepatic PCSK9 synthesis. Effect persists 6 months per dose after two loading injections, which makes in-office administration feasible. [2]

Because the mRNA-silencing approach works upstream of protein synthesis, inclisiran produces a more stable LDL-C reduction curve with less peak-to-trough variability than the monoclonal antibodies. [3]

Approved Agents, Formulations, and Dosing

Three agents hold FDA approval as of 2024. Each has a distinct dosing schedule and a slightly different indication profile.

Evolocumab (Repatha)

Evolocumab is the prototype PCSK9 inhibitor and the only agent approved for homozygous familial hypercholesterolemia (HoFH) in patients aged 13 and older. [4]

| Indication | Dose | Schedule | |---|---|---| | ASCVD / HeFH | 140 mg | Every 2 weeks SC | | ASCVD / HeFH | 420 mg | Once monthly SC | | HoFH | 420 mg | Once monthly SC |

The 420 mg monthly dose is delivered via the Pushtronex on-body infusion system over approximately 9 minutes, which some patients find more convenient than three separate 140 mg auto-injector injections.

Alirocumab (Praluent)

Alirocumab received FDA approval for ASCVD and HeFH. Its initial dosing label also allows a 75 mg every-2-weeks starting dose in patients who may not need maximal LDL-C lowering, with titration to 150 mg every 2 weeks if the LDL-C response is inadequate. [5]

| Starting dose | Titration | Schedule | |---|---|---| | 75 mg | Increase to 150 mg if LDL-C <50% reduction at 8 weeks | Every 2 weeks SC | | 150 mg | Fixed high-intensity dosing | Every 2 weeks SC |

Inclisiran (Leqvio)

Inclisiran is dosed as 284 mg SC at day 1, day 90, then every 6 months thereafter. [6] Because the injections are administered in a healthcare setting under the CMS "buy-and-bill" model, adherence rates in the ORION-9 and ORION-10 trials were effectively 100%, removing patient-level compliance as a variable.

Clinical Trial Evidence

The cardiovascular outcomes evidence for this class comes from two large randomized controlled trials for the monoclonal antibodies, plus a growing outcomes dataset for inclisiran.

FOURIER Trial (Evolocumab)

FOURIER (N=27,564) randomized patients with established ASCVD on optimized statin therapy to evolocumab 140 mg every 2 weeks or 420 mg monthly versus placebo. [7] At a median follow-up of 2.2 years:

• LDL-C fell from a median of 92 mg/dL to 30 mg/dL in the evolocumab group (a 59% reduction, P<0.001).
• The primary composite endpoint (cardiovascular death, MI, stroke, coronary revascularization, or unstable angina hospitalization) was reduced by 15% (HR 0.85, 95% CI 0.79 to 0.92, P<0.001).
• The key secondary endpoint of cardiovascular death, MI, or stroke was reduced by 20% (HR 0.80, 95% CI 0.73 to 0.88, P<0.001). [7]

The absolute risk reduction widened over time, with the benefit curve diverging more steeply after the first year, suggesting that the full cardiovascular benefit of sustained very low LDL-C accrues progressively. [7]

ODYSSEY OUTCOMES Trial (Alirocumab)

ODYSSEY OUTCOMES (N=18,924) enrolled patients within 1 to 12 months of an acute coronary syndrome and randomized them to alirocumab 75 mg every 2 weeks (with blinded titration up to 150 mg) versus placebo. [8] At a median follow-up of 2.8 years:

• Alirocumab reduced major adverse cardiovascular events (MACE: coronary heart disease death, non-fatal MI, fatal or non-fatal ischemic stroke, unstable angina) by 15% (HR 0.85, 95% CI 0.78 to 0.93, P<0.001).
• All-cause mortality was 3.5% in the alirocumab group versus 4.1% in the placebo group (HR 0.85, 95% CI 0.73 to 0.98), one of the first lipid-lowering trials to show a mortality signal. [8]

A pre-specified subgroup analysis found the greatest absolute benefit in patients with LDL-C ≥100 mg/dL at baseline, reinforcing the guideline principle of targeting patients with the highest residual risk. [8]

ORION Program (Inclisiran)

The ORION-9 (HeFH, N=482), ORION-10 (ASCVD, N=1,561), and ORION-11 (ASCVD or risk equivalent, N=1,617) trials collectively showed that inclisiran 284 mg SC reduced LDL-C by 49 to 54% at day 510 versus placebo (P<0.001 across all three studies). [9] Hard cardiovascular outcomes data are expected from the ongoing VICTORION-2P trial (estimated N=15,000, primary completion 2026).

Familial Hypercholesterolemia: A Priority Indication

FH is underdiagnosed and undertreated globally. Heterozygous FH affects approximately 1 in 250 people, and homozygous FH affects approximately 1 in 300,000. [10] Cascade screening first-degree relatives of an identified proband remains the most cost-effective detection strategy, per the 2018 AHA/ACC Cholesterol Guideline. [11]

HeFH Management

Patients with HeFH typically have LDL-C levels of 190 to 400 mg/dL at baseline. Even on high-intensity statins plus ezetimibe, many do not reach the guideline-recommended LDL-C target of <70 mg/dL (or <55 mg/dL for those with established ASCVD). Adding a PCSK9 inhibitor to dual oral therapy brings approximately 60 to 70% of HeFH patients to target. [10]

HoFH Management

Evolocumab is the only PCSK9 inhibitor with an HoFH indication. Because HoFH patients have absent or near-absent LDL receptor activity, the magnitude of LDL-C reduction is lower than in HeFH (approximately 30% versus 60%), but the absolute reduction can still be clinically meaningful. HoFH patients on evolocumab 420 mg monthly achieved a mean LDL-C reduction of 30.9% in the TESLA Part B trial (N=49, P<0.001). [12] LDL apheresis remains a complementary strategy for LDL-C levels that remain above 300 mg/dL despite maximal medical therapy.

Safety Profile and Monitoring

PCSK9 inhibitors have a favorable safety profile across the clinical trial database, which now encompasses more than 80,000 patient-years of exposure when FOURIER and ODYSSEY OUTCOMES are combined.

Injection-Site Reactions

Injection-site reactions (erythema, pain, bruising) occur in 2 to 5% of patients across the approved monoclonal antibodies, compared with 1 to 2% for placebo in randomized trials. [7] Reactions are generally mild and rarely lead to discontinuation (<1% discontinuation rate in FOURIER).

Neurocognitive Concerns

Early case reports raised the question of whether very low LDL-C might impair cognition. The EBBINGHAUS substudy of FOURIER (N=1,204 patients who completed neurocognitive testing) found no significant difference between evolocumab and placebo in any domain of the Cambridge Neuropsychological Test Automated Battery at 19 months (P<0.05 for all pre-specified outcomes favoring equivalence). [13] This finding effectively closed the neurocognitive concern from a trial-evidence standpoint.

Diabetes Risk

Unlike statins, PCSK9 inhibitors have not shown a consistent increase in new-onset diabetes mellitus in randomized trial populations. A Mendelian randomization analysis using UK Biobank data (N=337,138) found that genetically proxied PCSK9 inhibition was not associated with increased T2DM risk, in contrast to HMG-CoA reductase inhibition. [14]

Monitoring Parameters

Routine laboratory monitoring beyond a fasting lipid panel is not required. The 2018 AHA/ACC guideline recommends reassessing fasting lipids 4 to 12 weeks after initiation and every 3 to 12 months thereafter. [11] No hepatic enzyme or creatine kinase monitoring is mandated by the FDA label for any agent in this class.

Guideline Recommendations and Place in Therapy

The 2018 AHA/ACC Cholesterol Guideline and the 2022 ACC Expert Consensus Decision Pathway provide tiered guidance for when to add a PCSK9 inhibitor. [11] [15]

Primary Prevention

PCSK9 inhibitors are not routinely recommended in primary prevention unless LDL-C remains ≥190 mg/dL (consistent with FH phenotype) despite maximally tolerated statin therapy plus ezetimibe. The cost-effectiveness threshold of $100,000 per QALY is typically not met in primary prevention patients without very high absolute risk.

Secondary Prevention (Established ASCVD)

Per the 2022 ACC Expert Consensus Decision Pathway on Novel Therapies for LDL Reduction, patients with very high-risk ASCVD (defined as two or more major ASCVD events, or one major event plus two or more high-risk conditions) should have an LDL-C target <55 mg/dL. [15] The pathway recommends:

1. High-intensity statin (atorvastatin 40 to 80 mg or rosuvastatin 20 to 40 mg daily).
2. Add ezetimibe 10 mg daily if LDL-C remains above target.
3. Add a PCSK9 inhibitor if LDL-C remains ≥55 mg/dL despite step 1 and step 2.

The document states: "For patients with very high-risk ASCVD whose LDL-C level remains ≥55 mg/dL on maximally tolerated statin and ezetimibe therapy, it is reasonable to add a PCSK9 inhibitor." [15]

Post-ACS Timing

The ODYSSEY OUTCOMES trial enrolled patients as early as 1 month post-ACS, and subgroup analyses show consistent benefit regardless of time from index event to randomization. Some cardiologists initiate alirocumab before hospital discharge in patients presenting with LDL-C ≥70 mg/dL on background statin therapy, a practice supported by the ACC's pathway. [15]

Prescribing Considerations

Statin Intolerance

Both evolocumab and alirocumab hold an FDA approval extension for patients with statin intolerance. The GAUSS-3 trial (N=511) compared evolocumab monotherapy against ezetimibe in patients who had failed at least two statins due to muscle symptoms. [16] Evolocumab reduced LDL-C by 52.8% versus 16.7% for ezetimibe at 24 weeks, and 62.7% of patients assigned to evolocumab completed the trial without muscle symptom recurrence sufficient to discontinue. [16]

Drug Interactions

No cytochrome P450-based drug interactions exist for any agent in this class, because monoclonal antibodies are metabolized via proteolytic pathways and inclisiran acts intracellularly via RNA interference. Concomitant statin dose adjustments are not required. This clean interaction profile is particularly useful in post-transplant patients or those on complex anticoagulant regimens.

Pregnancy and Lactation

PCSK9 inhibitor use in pregnancy is not recommended. Animal reproductive studies with evolocumab showed no adverse developmental effects at exposures 6-fold higher than the maximum human dose, but human data are insufficient. [4] Women of childbearing potential should use effective contraception during treatment.

Special Populations

• Renal impairment: No dose adjustment needed for any agent; monoclonal antibodies do not undergo renal elimination.
• Hepatic impairment: Limited data for severe hepatic impairment (Child-Pugh C); use with caution.
• Pediatrics: Evolocumab is approved for HoFH in patients ≥13 years; alirocumab is approved for HeFH in patients ≥8 years (150 mg every 2 weeks). [5]

Cost, Access, and Adherence

The list price of injectable PCSK9 inhibitors has declined substantially since initial launch. After a 60% price reduction in 2018 to 2019, the wholesale acquisition cost (WAC) of evolocumab fell to approximately $5,850 per year. [4] Most commercial and Medicare Part D plans cover at least one agent with prior authorization.

Adherence to the twice-monthly injection schedule for monoclonal antibodies is approximately 60 to 70% at 12 months in real-world pharmacy claims data, compared with persistence rates of 40 to 50% for statins in similarly high-risk populations. The 6-month dosing interval for inclisiran may improve adherence further, though head-to-head real-world persistence data are not yet available.

A patient assistance program (PAP) offered through Amgen and Sanofi/Regeneron covers patients with household incomes below 400% of the federal poverty level at no out-of-pocket cost.

Comparing PCSK9 Inhibitors: A Side-by-Side Summary

| Feature | Evolocumab | Alirocumab | Inclisiran | |---|---|---|---| | Brand name | Repatha | Praluent | Leqvio | | Mechanism | mAb vs. PCSK9 protein | mAb vs. PCSK9 protein | siRNA silences PCSK9 mRNA | | Standard dose | 140 mg Q2W or 420 mg QM | 75 to 150 mg Q2W | 284 mg at D1, D90, then Q6M | | LDL-C reduction | ~59 to 60% | ~55 to 60% | ~50 to 54% | | HoFH approval | Yes (≥13 yrs) | No | No | | CV outcomes trial | FOURIER (N=27,564) | ODYSSEY OUTCOMES (N=18,924) | VICTORION-2P (ongoing) | | CV outcomes data | 15% MACE reduction | 15% MACE reduction | Pending | | Administration setting | Self-administered | Self-administered | HCP office |

Frequently Asked Questions